期刊文献+

Inhibitory effect of 2'-o-methoxyethyl-modified antisense oligonucleotides targeting vascular endothelial growth factor A on SKOV3 human ovarian cancer cells

Inhibitory effect of 2'-o-methoxyethyl-modified antisense oligonucleotides targeting vascular endothelial growth factor A on SKOV3 human ovarian cancer cells
原文传递
导出
摘要 Background Ovarian cancers are often at an advanced stage at diagnosis because early detection is difficult. The poor prognosis of ovarian cancers highlights the crucial need to develop better therapeutic agents and strategies. The objective of this study was to investigate the inhibitory effects of a new modified antisense oligonucleotides targeting vascular endothelial growth factor A (VEGF-A) in SKOV3 ovarian cancer cells.Methods Antisense oligonucleotides targeting VEGF-A was designed, synthesized and transfected into SKOV3ovarian cancer cells. Western blotting and real-time RT-PCR were used to analyze the inhibitory effects of antisense oligonucleotides on VEGF-A protein and mRNA expression. Transwell matrix assay was used to detect cell migration inhibition.Results The antisense oligonucleotides targeting VEGF-A significantly decreased VEGF-A protein and mRNA expression and inhibited cell migration in SKOV3 ovarian cancer cells.Conclusions This new modified antisense oligonucleotides targeting VEGF-A can decrease VEGF-A expression and inhibit cell migration in SKOV3 ovarian cancer cells. This new oligonucleotides may be a promising therapeutic agent for ovarian cancers Background Ovarian cancers are often at an advanced stage at diagnosis because early detection is difficult. The poor prognosis of ovarian cancers highlights the crucial need to develop better therapeutic agents and strategies. The objective of this study was to investigate the inhibitory effects of a new modified antisense oligonucleotides targeting vascular endothelial growth factor A (VEGF-A) in SKOV3 ovarian cancer cells.Methods Antisense oligonucleotides targeting VEGF-A was designed, synthesized and transfected into SKOV3ovarian cancer cells. Western blotting and real-time RT-PCR were used to analyze the inhibitory effects of antisense oligonucleotides on VEGF-A protein and mRNA expression. Transwell matrix assay was used to detect cell migration inhibition.Results The antisense oligonucleotides targeting VEGF-A significantly decreased VEGF-A protein and mRNA expression and inhibited cell migration in SKOV3 ovarian cancer cells.Conclusions This new modified antisense oligonucleotides targeting VEGF-A can decrease VEGF-A expression and inhibit cell migration in SKOV3 ovarian cancer cells. This new oligonucleotides may be a promising therapeutic agent for ovarian cancers
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第10期1573-1575,共3页 中华医学杂志(英文版)
关键词 vascular endothelial growth factor A ovarian cancer antisense oligonucleotides TRANSFECTION vascular endothelial growth factor A ovarian cancer antisense oligonucleotides transfection
  • 引文网络
  • 相关文献

参考文献14

  • 1Kurman RJ,Visvanathan K,Roden R,Wu TC,Shih IeM.Early detection and treatment of ovarian cancer:shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.Am J Obstet Gynecol 2008; 198:351-356.
  • 2O'Byrne KJ,Koukourakis MI,Giatromanolaki A,Cox G,Turley H,Steward WP,et al.Vascular endothelial growth factor,platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.Br J Cancer 2000;82:1427-1432.
  • 3Robinson CJ,Stringer SE.The splice variants of vascular endothelial growth factor (VEGF) and their receptors.J Cell Sci 2001; 114:853-865.
  • 4Campos SM,Ghosh S.A current review of targeted therapeutics for ovarian cancer.J Oncol 2010; 2010:149362.
  • 5Livak KJ,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method.Methods 2001; 25:402-408.
  • 6Bamberger ES,Perrett CW.Angiogenesis in epithelian ovarian cancer.Mol Pathol 2002; 55:348-359.
  • 7Boocock CA,Charnock-Jones DS,Sharkey AM,McLaren J,Barker PJ,Wright KA,et al.Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.J Natl Cancer Inst 1995; 87:506-516.
  • 8Byrne AT,Ross L,Holash J,Nakanishi M,Hu L,Hofmann JI,et al.Vascular endothelial growth factor-trap decreases tumor burden,inhibits ascites,and causes dramatic vascular remodeling in an ovarian cancer model.Clin Cancer Res 2003; 9:5721-5728.
  • 9Burger RA,Sill MW,Monk BJ,Greer BE,Sorosky JI.Phase Ⅱ trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer:a Gynecologic Oncology Group Study.J Clin Oncol 2007; 25:5165-5171.
  • 10Zhou J,Gan N,Zhang W,Lu W,Xie X.Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor.J Obstet Gynaecol Res 2010; 36:232-238.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部